FTC
This article was originally published in The Tan Sheet
Executive Summary
Drug patents should not be listed in Orange Book by FDA if they claim unapproved aspects of a drug, commission suggests in May 16 citizen petition to agency. "Any patent claiming only an unapproved component, an unapproved formulation or an unapproved use of a drug product" should not be allowed in Orange Book, FTC says. Petition comes in response to complaints from generic drug manufacturers that innovator companies are filing large numbers of late-listed patents to thwart private label competition. FTC is conducting an inquiry into this and other anticompetitive practices in drug industry (1"The Tan Sheet" Oct. 16, 2000, p. 13)
|
Drug patents should not be listed in Orange Book by FDA if they claim unapproved aspects of a drug, commission suggests in May 16 citizen petition to agency. "Any patent claiming only an unapproved component, an unapproved formulation or an unapproved use of a drug product" should not be allowed in Orange Book, FTC says. Petition comes in response to complaints from generic drug manufacturers that innovator companies are filing large numbers of late-listed patents to thwart private label competition. FTC is conducting an inquiry into this and other anticompetitive practices in drug industry (1 (Also see "FTC Generic Drug Survey To Gather Information On Late-Listed Patents" - Pink Sheet, 16 Oct, 2000.)). |